Expediting Discovery and Development: A Pharmaceutical Case Study



How did Mindbreeze help a pharmaceutical company speed up time to market by 50%?

The organization needed to analyze clinical trial data, drug information, and review applications faster and more consistently.

Read the full case study

 

The Problems:

  • Life science organizations often face challenges managing and utilizing their data effectively to make quicker and more informed decisions.
  • Access to scattered data across various systems makes it practically impossible for researchers and authorities to make life-changing discoveries in a highly regulated industry.
  • More than 17,000 employees (all needing critical information).

 

So, how did Mindbreeze help?

AI Features Used:

  • Search-driven analytics for autosuggestions based on user search history, popular queries, and document keywords.
  • Entity Recognition Service for automatic extraction of necessary information from large documents and datasets.
  • Semantic Relations Service to identify and extract correlations of existing information and provide relevant results on a priority basis.

 

What happened?

With Mindbreeze, the company was able to improve and speed up time to market by 50% by freeing siloed data from legacy infrastructures, allowing them to swiftly identify and address inquiries.

Read the full case study

How can we help your company expedite discovery and development?

For more information, you can also visit our webpage dedicated to R&D.

Latest Blogs

How AI Quickly Connects You with the Right Subject Matter Experts

Felix Breiteneder

Mindbreeze InTend simplifies SME identification and collaboration by using AI to pinpoint the needed expertise efficiently.

Mindbreeze Podcast Presents: “Learn About Mindbreeze InTend – RFP and Proposal Solution”

Jeremy Wise

Throughout this episode, we'll uncover the transformative capabilities of Mindbreeze InTend, an end-to-end solution designed to support bid and proposal managers at every stage of the tender lifecycle.